What type of study is this?

This is a Quantitative Study study.

The metric matters: Comparing end-of-life (EOL) systemic anticancer therapy use (SACT) in two quality indicators.

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals discrepancies in EOL systemic anticancer therapy metrics from ASCO and Vizient, suggesting varied implications for care quality.

EOL systemic anticancer therapy use differed significantly between ASCO and Vizient metrics, impacting care evaluation.
ASCO reported an overall EOL SACT use of 6.4%, while Vizient reported 0.12%, indicating wide variations in care metrics.
Methodological differences in definitions between ASCO and Vizient affect patient inclusion and outcomes reported.
Variability in drug definitions and reporting requirements may influence quality rankings and reimbursement strategies.

Xiang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis reveals discrepancies in EOL systemic anticancer therapy metrics from ASCO and Vizient, suggesting varied implications for care quality.